Rhythm Biosciences Limited · ASX:RHY
Rhythm Biosciences — Investor Presentation (April 2022)
12 slides from Rhythm Biosciences's investor presentation, Apr 5, 2022
Slide 1: Investor Presentation
Investor Presentation 5 April 2022 ASX:RHY A transformative and predictive cancer diagnostics technology company
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Rhythm Biosciences Limited (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undert
Slide 3: Introduction
Introduction Rhythm’s initial product, ColoSTAT® is a simple, low-cost blood test for the early detection of colorectal cancer for global mass- market screening. IP protection secured in all major international jurisdictions. Commenced platform technology program for multiple / pan cancer targets. 3
Slide 4: ColoSTAT® Highlights
ColoSTAT® Highlights Disruptive and transformative technology Significantly cheaper and easier to administer Globally addressable markets Performance better than market standard Manufacturing & Patents secured Initial revenues targeted for 2022 4
Slide 5: Company Overview
Company Overview Capital Structure Share Price Chart ASX Code RHY $7,000,000 $2.50 Share Price (at 4 April 2022) $1.76 $6,000,000 $2.00 $5,000,000 Shares on Issue 214.1 M $4,000,000 $1.50 Unlisted Options 16.8 M $3,000,000 $1.00 Market Capitalisation $376.8 M $2,000,000 $0.50 $1,000,000 Cash in bank
Slide 6: Market Opportunity / Addressable Market
Market Opportunity / Addressable Market US$38 billion addressable screening value in priority markets1 Colorectal Cancer Screening Market Population Number of people over 50 years of age eligible for screening Country Screening participation Addressable population United States 63% 94 million $12Bn
Slide 7: Australia – Growth of CRC in younger age groups
Australia – Growth of CRC in younger age groups 25 – 29 years old 30 – 34 years old 35 – 39 years old 1990 1995 2000 2005 2010 2015 2020 1990 1995 2000 2005 2010 2015 2020 1990 1995 2000 2005 2010 2015 2020 0 0 0 1 1 1 2 2 2 3 3 3 4 4 4 5 5 5 6 6 6 7 7 7 8 8 8 9 9 9 10 10 10 11 11 11 12 12 12 13 13
Slide 8: ColoSTAT® Performance
ColoSTAT® Performance “83% of unscreened participants prefer a blood test over a faecal test”1 ColoSTAT® Sensitivity Performance Comparison • Highly accurate ColoSTAT® was shown to be 35% more accurate at detecting colorectal cancer than 85% the current market standard Faecal Immunochemical Test (FI
Slide 9: Clinical Trial (Study 7) – Performance In A Clinical Setting
Clinical Trial (Study 7) – Performance In A Clinical Setting PRIMARY ENDPOINT SUCCESSFULLY ACHIEVED: Performance of ColoSTAT® for detection of CRC relative to colonoscopy (Sensitivity and Specificity). Key Steps (not exhaustive list): Close final clinical trial site. Underway. Complete patient
Slide 10: Platform Technology Expansion
Platform Technology Expansion • The expansion program is expected to be significantly shortened, leveraging the Company’s lead biomarker which exhibits pan-cancerous properties; • A platform expansion program identified a number of additional cancer target markets that have formed a new Research and
Slide 11: Future Catalysts
Future Catalysts Clinical Trial (Study 7) completion and clinical study report completion; Technical file complete for ARTG listing for TGA submission and approval; Identify and progress partnering / commercialisation deals (Domestic and International); International country submissions / re
Slide 12: Glenn Gilbert CEO and Managing Director, Rhythm Biosciences
Glenn Gilbert CEO and Managing Director, Rhythm Biosciences glenn.gilbert@rhythmbio.com +61 3 8256 2880 www.rhythmbio.com 12
Rhythm Biosciences — Investor Presentation (April 2022) on 6ix